Drawing for TURN THERAPEUTICS

USPTO serial 88044977

TURN THERAPEUTICS

Reviewed by CopyMark Law Group

Reg. 6283602Status 700Renewal
Filing date
Status date
Registration date
Mar 2, 2021
Examiner
GILLES, DEBORAH LYNN MEINERS
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with TURN THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment and prevention of infectious diseases; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical skin lotions; Analgesic and muscle relaxant pharmaceutical preparations; Antibacterial pharmaceuticals; Balms for pharmaceutical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for infectious diseases; Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Ocular pharmaceuticals; Plant extracts for pharmaceutical purposesACTIVEJul 31, 2019
042Development of pharmaceutical preparations and medicines; Research and development in the pharmaceutical and biotechnology fields; Research on the subject of pharmaceuticals; Testing of pharmaceuticalsACTIVENov 30, 2018

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 20, 2026PUM1OFFICE ACTION ISSUED POU1—
May 20, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 24, 2026ES8RTEAS SECTION 8 RECEIVED—
Mar 2, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Mar 2, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 28, 2021SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jan 27, 2021CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jan 27, 2021SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jan 25, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jan 6, 2021IUAFUSE AMENDMENT FILED—
Jan 6, 2021EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Sep 2, 2020ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jul 10, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 8, 2020EX3GSOU EXTENSION 3 GRANTED—
Jul 8, 2020EXT3SOU EXTENSION 3 FILED—
Jul 8, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 4, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 2, 2020EX2GSOU EXTENSION 2 GRANTED—
Jan 2, 2020EXT2SOU EXTENSION 2 FILED—
Jan 2, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 9, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 5, 2019EX1GSOU EXTENSION 1 GRANTED—
Jul 5, 2019EXT1SOU EXTENSION 1 FILED—
Jul 5, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 29, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 29, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 8, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 13, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 13, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 24, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 9, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 8, 2018ALIEASSIGNED TO LIE—
Sep 22, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 22, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Sep 22, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 22, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 22, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 21, 2018DOCKASSIGNED TO EXAMINER—
Jul 24, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 23, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance